The DNA damage checkpoint is activated during residual tumour cell survival to methotrexate treatment as an initial step of acquired drug resistance.
In the process of acquired drug resistance, the absence of tumour cell subpopulations already resistant before treatment implies an initial adaptive stage of cell growth following drug exposure that, under the selective pressure of the drug, allows the emergence of stably resistant cell variants. Here, we show that p53-defective HT-29 colon cancer cells overcome methotrexate-induced cell death owing to DNA damage checkpoint-mediated cell survival at the adaptive stage that precedes stable resistance acquisition. HT-29 cell cycle progression was dramatically delayed in the presence of a lethal dose of methotrexate, leading to DNA damage during S-phase transition and to cell death as treated cells progressed to G2 and M phases. As a result, the DNA damage checkpoint was induced as indicated by the presence of activated phosphorylated forms of checkpoint proteins Chk1 and Rad9. As we recently described, in-vitro resistance to methotrexate occurs without cell subpopulations already resistant before treatment, hence resistance is acquired through a multistep process that includes an early stage of transient cell survival. Our present results showed that this acute cell survival stage was due to a minor percentage of cells that could complete the first division cycle after drug exposure. Cell survival was enhanced by drug withdrawal during S-phase transition and suppressed if drug withdrawal was followed by treatment with the checkpoint-inhibitor drug caffeine. These results thus point to checkpoint-mediated transient adaptation as a target to prevent the emergence of acquired resistance to methotrexate.
de Anta
Josep M
JM
Cellular and Molecular Biology Unit, Municipal Institute of Medical Research, Barcelona, and Research Unit, University Hospital of Canarias, Tenerife, Spain.
Pérez-Castro
Antonio J
AJ
Freire
Raimundo
R
Mayol
Xavier
X
D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology; D002453:Cell Cycle / Q000187:drug effects; D018797:Cell Cycle Proteins / Q000378:metabolism; D002470:Cell Survival / Q000187:drug effects; D000071877:Checkpoint Kinase 1; D004249:DNA Damage / Q000187:drug effects; D019008:Drug Resistance, Neoplasm; D019073:HT29 Cells; D006657:Histones / Q000378:metabolism; D006801:Humans; D008727:Methotrexate / Q000494:pharmacology*; D008954:Models, Biological; D018365:Neoplasm, Residual; D010766:Phosphorylation / Q000187:drug effects; D011494:Protein Kinases / Q000378:metabolism* / Q000502:physiology*
D000964:Antimetabolites, Antineoplastic; D018797:Cell Cycle Proteins; C468783:H2AX protein, human; D006657:Histones; C069930:rad9 protein; D011494:Protein Kinases; C000605867:CHEK1 protein, human; D000071877:Checkpoint Kinase 1; D008727:Methotrexate